UC San Diego Sparks New Cancer-Focused Startup, Oncternal, with Exclusive Antibody License

Oncternal Therapeutics, a new cancer-focused biotechnology startup, has signed a wide-ranging licensing agreement with UC San Diego to develop and commercialize antibodies and antibody-related binding agents.

Oncternal is based on the pioneering research of UC San Diego scientist and clinician Thomas J. Kipps, Distinguished Professor, Evelyn and Edwin Tasch Chair in Cancer Research, and deputy director of research operations at the Moores Cancer Center on campus. … Read the Full Story from the UC San Diego Newsroom